Morgan Stanley Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $64
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit maintains an Overweight rating on Halozyme Therapeutics (NASDAQ:HALO) and raises the price target from $59 to $64.
August 07, 2024 | 4:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley analyst Vikram Purohit maintains an Overweight rating on Halozyme Therapeutics and raises the price target from $59 to $64.
The raised price target and maintained Overweight rating from a reputable analyst at Morgan Stanley is likely to positively impact investor sentiment and drive short-term price appreciation for Halozyme Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100